RxDoctor Payments Data

Valerie Cavaliere

Acute Care · Thomasville, GANPI 1346934528

Payments from drug & device makers

$1,846in general payments, 2019–2025

Across 80 payments — averaging $23.07 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Abiomed$282
  • Amgen$251
  • AstraZeneca$176
  • E.r. Squibb & Sons, L.L.C.$170
  • Merck$141
  • Penumbra, Inc.$137
  • plus $689 from 10 others

What the payments were for

  • Food & beverage$1,846100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,846 in reported general payments places this provider in the 80th percentile of 679 acute care providers in Georgia.

See all acute care providers in Georgia

Medicare billing

Part B allowed, 2024
$13,277
Medicare patients
100
Services billed
157

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
FarxigaDapagliflozin Propanediol36$28,318
EntrestoSacubitril/Valsartan31$25,038
EliquisApixaban20$14,848
Metoprolol Succinate89$823
Ranolazine ErRanolazine15$785
ClopidogrelClopidogrel Bisulfate70$564
Ezetimibe30$516
Atorvastatin Calcium66$429
Isosorbide Mononitrate ErIsosorbide Mononitrate24$340
Losartan Potassium45$280
Nitroglycerin24$204
Carvedilol35$202
Rosuvastatin Calcium25$155
Furosemide41$149
Potassium Chloride19$143

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AstraZenecaFarxiga$176$28,31836 claims
NovartisEntresto$126$25,03831 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 679 acute care providers in Georgia.

Other acute care in Thomasville

See the full list for Georgia

Where these figures come from

Is this you, or does something look wrong? →